Arecor Therapeutics PLC (FWB:6UI) Financings

Arecor Therapeutics PLC

Financings

RaiseDateIn US dollars
New ordinary shares (Retail Offer Shares)
Closed: £130,000 raised · GBX 68 a share · Singer Capital Markets +1
Dealers: Singer Capital Markets (lead), Singer Capital Markets Securities Limited
Use of proceeds: General working capital and to strengthen the Group's balance sheet
Oct 7, 2026US$171,735
Private placement of new ordinary shares
Update: about £5M · GBX 68 a share · Singer Capital Markets
Dealers: Singer Capital Markets (lead)
Use of proceeds: Strengthen balance sheet, extend cash runway to December 2027 and fund critical-path insulin development activities
Sep 30, 2026US$6.61M
Royalty financing with warrants over ordinary shares
Announced: up to US$11M · Warrants at GBX 67.39 for 120 months
Buyers: Ligand Pharmaceuticals Inc. (royalty financing of up to $11 million; warrants over 1,002,739 ordinary shares); Ligand (pays up to $11.0 million for royalty and fee rights and receives warrants over 1,002,739 ordinary shares); Ligand Pharmaceuticals Incorporated (pays up to $11.0 million for royalty rights and receives warrants over 1,002,739 ordinary shares)
Use of proceeds: Start AT278 Phase 2-enabling activities and extend cash runway to 1H 2027
Sep 25, 2025

Read by 6ix AI from the company's releases